(Total Views: 450)
Posted On: 01/10/2020 11:32:49 AM
Post# of 149382
If off-label catches up (this needs the word to be propagated around physicians and patients) it will spread as fire if the results continue to be as good.
Remember, in Oncology all a drug has to do is to extend the overall survival of the patients with good quality of life (ideally no SAE's).
It seems that Leronlimab checks both points with flying colors (if current data trends are confirmed with more patients).
Off-label can be a HUGE market, more so Internationally where culturally speaking, people are more "adventurous" regarding heir treatments and some countries are much less regulated, which in this case, would work for their advantage being able to access the drug. This both, for HIV and Oncology.
The question is: who will commercialize it (and what kind of pricing will be tagged for different indications) ?? . We need to start getting or act together on this one as once it catches it might very well grow without control (pun intended).
Remember, in Oncology all a drug has to do is to extend the overall survival of the patients with good quality of life (ideally no SAE's).
It seems that Leronlimab checks both points with flying colors (if current data trends are confirmed with more patients).
Off-label can be a HUGE market, more so Internationally where culturally speaking, people are more "adventurous" regarding heir treatments and some countries are much less regulated, which in this case, would work for their advantage being able to access the drug. This both, for HIV and Oncology.
The question is: who will commercialize it (and what kind of pricing will be tagged for different indications) ?? . We need to start getting or act together on this one as once it catches it might very well grow without control (pun intended).
(2)
(0)Scroll down for more posts ▼
